ISRCTN13275753CompletedNot Applicable
Randomised placebo controlled trial of antihypertensive agents for the prevention of cardiovascular complications of hypertensio
Sponsor not defined - Record provided by the Medical Research Council (UK)0 sites4,396 target enrollmentStarted: September 8, 2005Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 4,396
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Men and women aged 65-74 at recruitment in 226 general practices in the Medical Research Council's General Practice Research Framework. Systolic blood pressure 160-209 mmHg and diastolic pressure less than 115 mmHg.
Exclusion Criteria
- •Secondary hypertension; already on antihypertensive treatment; accepted indication for antihypertensive treatment; myocardial infarction or stroke within previous three months; impaired renal function; presence of angina, intermittent claudication, diabetes, gout, bronchial asthma, serious intercurrent disease including malignant hypertension.
Investigators
Similar Trials
Active, not recruiting
Phase 1
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer.Serious epithelial ovarian cancer including primary peritoneal and fallopian tube malignanciesMedDRA version: 17.1Level: PTClassification code 10033160Term: Ovarian epithelial cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003812-36-ESMorphotek Inc214
Active, not recruiting
Not Applicable
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First RelapsePrima recidiva di carcinoma ovarico epiteliale non mucinoso platino-sensibile incluso carcinoma peritoneale primario o tumore delle tube di falloppioMedDRA version: 14.1Level: PTClassification code 10033160Term: Ovarian epithelial cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-005872-29-ITEisai Limited1,080
Active, not recruiting
Phase 1
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer.Serious epithelial ovarian cancer including primary peritoneal and fallopian tube malignanciesMedDRA version: 20.0Level: PTClassification code 10033160Term: Ovarian epithelial cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003812-36-GBEisai Limited210
Active, not recruiting
Not Applicable
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First RelapseFirst relapse of platinum-sensitive non-mucinous epithelial ovarian cancer including primary peritoneal or fallopian tube malignanciesMedDRA version: 14.0Level: PTClassification code 10033160Term: Ovarian epithelial cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-005872-29-ATEisai Limited1,080
Active, not recruiting
Phase 1
A Study to evaluate Efficacy, Safety, Tolerability and Effects of TAK-341 in the human body in patients with Multiple System AtrophyMedDRA version: 21.1Level: PTClassification code 10064060Term: Multiple system atrophySystem Organ Class: 10029205 - Nervous system disordersMultiple System AtrophyEUCTR2022-000336-28-DETakeda Development Center Americas, Inc.138